STOCK TITAN

Entrada Therapeutics Inc - TRDA STOCK NEWS

Welcome to our dedicated news page for Entrada Therapeutics (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entrada Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entrada Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.07%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.76%
Tags
none
Entrada Therapeutics Inc

Nasdaq:TRDA

TRDA Rankings

TRDA Stock Data

435.13M
13.57M
15.46%
78.68%
5.26%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About TRDA

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.